These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28263231)

  • 1. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
    Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
    Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.
    Noguchi R; Yano H; Gohda Y; Suda R; Igari T; Ohta Y; Yamashita N; Yamaguchi K; Terakado Y; Ikenoue T; Furukawa Y
    Cancer Med; 2015 Dec; 4(12):1809-16. PubMed ID: 26475379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Next-Generation Sequencing Improves the Prognostication of Patients with Disseminated Appendiceal Mucinous Neoplasms (Pseudomyxoma Peritonei).
    Wald AI; Pingpank JF; Ongchin M; Hall LB; Jones H; Altpeter S; Liebdzinski M; Hamed AB; Derby J; Nikiforova MN; Bell PD; Paniccia A; Zureikat AH; Gorantla VC; Rhee JC; Thomas R; Bartlett DL; Smith K; Henn P; Theisen BK; Shyu S; Shalaby A; Choudry MHA; Singhi AD
    Ann Surg Oncol; 2023 Nov; 30(12):7517-7526. PubMed ID: 37314541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei.
    Lin YL; Zhu JQ; Ma RQ; Meng W; Wang ZY; Li XB; Ma R; Wu HL; Xu HB; Gao Y; Li Y
    Mol Cancer Res; 2024 Jan; 22(1):70-81. PubMed ID: 37768171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.
    Miura JT; Xiu J; Thomas J; George B; Carron BR; Tsai S; Johnston FM; Turaga KK; Gamblin TC
    Cancer Biol Ther; 2015; 16(5):764-9. PubMed ID: 25778705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination.
    Villarejo Campos P; Vázquez-Borrego MC; Martínez-Quintanilla J; Cabot D; Romero-Ruíz A; Granados-Rodríguez M; Bura FI; García-Arranz M; García-Olmo D; Arjona-Sánchez A
    Eur J Surg Oncol; 2024 Jul; 50(7):108395. PubMed ID: 38735236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision oncology and systemic targeted therapy in Pseudomyxoma Peritonei.
    Martínez-Quintanilla J; Cabot D; Sabia D; Arqués O; Vergés J; Chicote I; Bijelic L; Cabellos L; Alcántara AM; Ramos I; Barrios P; Crusellas O; Palacio LM; Cámara JA; Barriuso J; Jiménez JJ; Muñoz-Torres P; Nonell L; Flores R; Médico E; Guaglio M; Ros J; Élez E; Tabernero J; Aziz O; Deraco M; Palmer HG
    Clin Cancer Res; 2024 Jul; ():. PubMed ID: 39018564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of a small-molecule inhibitor of KRAS
    Vázquez-Borrego MC; Granados-Rodríguez M; Bura FI; Martínez-López A; Rufián-Andújar B; Valenzuela-Molina F; Rodríguez-Ortiz L; Haro-Yuste S; Moreno-Serrano A; Ortega-Salas R; Pineda-Reyes R; Michán C; Alhama J; Romero-Ruiz A; Arjona-Sánchez Á
    Exp Hematol Oncol; 2023 Dec; 12(1):102. PubMed ID: 38066554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiles of brain metastases: Prioritization of therapeutic targets.
    Ferguson SD; Zheng S; Xiu J; Zhou S; Khasraw M; Brastianos PK; Kesari S; Hu J; Rudnick J; Salacz ME; Piccioni D; Huang S; Davies MA; Glitza IC; Heymach JV; Zhang J; Ibrahim NK; DeGroot JF; McCarty J; O'Brien BJ; Sawaya R; Verhaak RGW; Reddy SK; Priebe W; Gatalica Z; Spetzler D; Heimberger AB
    Int J Cancer; 2018 Dec; 143(11):3019-3026. PubMed ID: 29923182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.
    Smaglo BG; Tesfaye A; Halfdanarson TR; Meyer JE; Wang J; Gatalica Z; Reddy S; Arguello D; Boland PM
    Oncotarget; 2015 Dec; 6(41):43594-604. PubMed ID: 26498363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ependymomas overexpress chemoresistance and DNA repair-related proteins.
    Ferguson SD; Zhou S; Xiu J; Hashimoto Y; Sanai N; Kim L; Kesari S; de Groot J; Spetzler D; Heimberger AB
    Oncotarget; 2018 Jan; 9(8):7822-7831. PubMed ID: 29487694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models.
    Fleten KG; Lund-Andersen C; Waagene S; Abrahamsen TW; Mørch Y; Boye K; Torgunrud A; Flatmark K
    Transl Oncol; 2020 Aug; 13(8):100793. PubMed ID: 32447231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
    Borazanci E; Millis SZ; Kimbrough J; Doll N; Von Hoff D; Ramanathan RK
    J Gastrointest Oncol; 2017 Feb; 8(1):164-172. PubMed ID: 28280620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomyxoma peritonei: natural history and treatment.
    Mittal R; Chandramohan A; Moran B
    Int J Hyperthermia; 2017 Aug; 33(5):511-519. PubMed ID: 28540829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms.
    Li Z; Roth R; Rock JB; Lehman A; Marsh WL; Suarez A; Frankel WL
    Am J Clin Pathol; 2017 May; 147(5):484-491. PubMed ID: 28340228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota modulation of chemotherapy efficacy and toxicity.
    Alexander JL; Wilson ID; Teare J; Marchesi JR; Nicholson JK; Kinross JM
    Nat Rev Gastroenterol Hepatol; 2017 Jun; 14(6):356-365. PubMed ID: 28270698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care.
    Valasek MA; Thung I; Gollapalle E; Hodkoff AA; Kelly KJ; Baumgartner JM; Vavinskaya V; Lin GY; Tipps AP; Hosseini MV; Lowy AM
    PLoS One; 2017; 12(6):e0179216. PubMed ID: 28591173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing.
    Matson DR; Xu J; Huffman L; Barroilhet L; Accola M; Rehrauer WM; Weisman P
    Am J Case Rep; 2017 May; 18():558-562. PubMed ID: 28526814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed Tomography Follow-Up Assessment of Patients with Low-Grade Appendiceal Mucinous Neoplasms: Evaluation of Risk for Pseudomyxoma Peritonei.
    Tiselius C; Kindler C; Shetye J; Letocha H; Smedh K
    Ann Surg Oncol; 2017 Jul; 24(7):1778-1782. PubMed ID: 28474197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.